Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease

Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):1839-1850. doi: 10.1161/ATVBAHA.120.315448. Epub 2021 Apr 22.

Abraham J P Teunissen¹, Mandy M T van Leent¹, Geoffrey Prévot¹, Eliane E S Brechbühl^{1

2}, Carlos Pérez-Medina^{1

3}, Raphaël Duivenvoorden^{1

4}, Zahi A Fayad¹, Willem J M Mulder^{1

5

6

7}

¹ Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York (A.J.P.T., M.M.T.v.L., G.P., E.E.S.B., C.P.-M., R.D., Z.A.F., W.J.M.M.).
² Institute of Materials, School of Engineering (STI), École Polytechnique Fédérale de Lausanne, Switzerland (E.E.S.B.).
³ Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.P.-M.).
⁴ Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (R.D.).
⁵ Department of Medical Biochemistry, Amsterdam University Medical Centers, The Netherlands (M.M.T.v.L.).
⁶ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York (W.J.M.M.).
⁷ Department of Biochemical Engineering, Laboratory of Chemical Biology, Eindhoven University of Technology, The Netherlands (W.J.M.M.).

Abstract

[Figure: see text].

Keywords: atherosclerosis; immunotherapy; inflammation; nanoparticle; nanotechnology.